TransMedics Group, Inc. (TMDX) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong margins ⢠High cash flow ⢠Premium valuation TMDX shows strong profitability, cash generation, and liquidity, but its high valuation, moderate leverage, and only average asset efficiency make the stock look fully priced.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Mid-110s Resistance ⢠Volatile Rebound Support Level: $100 Resistance Level: $109â$116 TMDX has improved over the last month and is holding above $100, but it remains below its early-March highs and needs to clear the $109â$116 resistance zone to confirm a stronger recovery.
Sentiment & News
Key News Insights: ⢠CHOPS launch ⢠Clinical updates ⢠Earnings catalyst TransMedics is showing continued momentum with new organ-transplant technology, upcoming clinical updates, and an earnings catalyst ahead, while the stock and investors remain responsive to its growth outlook.
AI Summary
TMDX has evolved from a pure growth story into a profitable, cash-rich execution story with real optionality from fleet expansion, international growth, and next-gen trials, but at these premium multiples the stock now hinges on flawless delivery because any margin slip, trial delay, or capital-allocation misstep could hit the shares hard.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |